<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40948240</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1753-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of diabetes</Title><ISOAbbreviation>J Diabetes</ISOAbbreviation></Journal><ArticleTitle>Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>e70156</StartPage><MedlinePgn>e70156</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70156</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/1753-0407.70156</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This randomized controlled trial (RCT) was designed to evaluate the effects of sitagliptin on diabetic foot ulcers (DFUs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a randomized, open-label clinical trial. The participants were assigned to either the control group, which received standard conventional therapy alone, or the sitagliptin treatment group, which received an oral administration of sitagliptin (100&#x2009;mg once daily) in conjunction with standard conventional therapy. The primary endpoints were the ulcer healing rate and adverse reactions. The secondary endpoints included the time to ulcer healing, peripheral blood CD34+ endothelial progenitor cells (EPCs) count, serum levels of stromal cell-derived factor-1&#x3b1; (SDF-1&#x3b1;), and glycosylated hemoglobin A1c (HbA1c).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 62 subjects were enrolled in this trial, with 31 individuals assigned to each group. One participant from each group was lost to follow-up. Posttrial analysis revealed that, compared with the control group, the sitagliptin group demonstrated a significantly greater reduction in ulcer area and improved efficacy in terms of ulcer healing (p&#x2009;&lt;&#x2009;0.05). Although not statistically significant (p&#x2009;=&#x2009;0.071), the sitagliptin group also tended to have a shorter ulcer healing time. Additionally, the sitagliptin group presented significantly greater numbers of CD34+ EPCs and higher SDF-1&#x3b1; levels compared to the control group (p&#x2009;&lt;&#x2009;0.05). No statistically significant difference in HbA1c levels was observed between the two groups (p&#x2009;&gt;&#x2009;0.05). No adverse events associated with sitagliptin treatment were reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The DPP-4 inhibitor sitagliptin may facilitate the healing of DFUs independent of its glucose-lowering effects, potentially by enhancing the mobilization of CD34&#x2009;+&#x2009;EPCs in peripheral blood.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Registration number: ChiCTR 2000029230, Approval date: 2020/01/19.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Journal of Diabetes published by Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Management Center, General Practice Center, West China Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Research Center for Diabetic Foot, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nenggang</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Research Center for Diabetic Foot, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ran</LastName><ForeName>Xingwu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6634-1241</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Research Center for Diabetic Foot, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2024YFFK0290</GrantID><Agency>Science and Technology Bureau of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>2024NSFSC1622</GrantID><Agency>Science and Technology Bureau of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>2019YFS0306</GrantID><Agency>Science and Technology Bureau of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>23LCYJ042</GrantID><Agency>Health Commission of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>ZYGD24005</GrantID><Agency>1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University</Agency><Country/></Grant><Grant><GrantID>GYYX24002</GrantID><Agency>1.3.5 Project of Center for High Altitude Medicine, West China Hospital, Sichuan University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Diabetes</MedlineTA><NlmUniqueID>101504326</NlmUniqueID><ISSNLinking>1753-0407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>TS63EW8X6F</RegistryNumber><NameOfSubstance UI="D000068900">Sitagliptin Phosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068900" MajorTopicYN="Y">Sitagliptin Phosphate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017719" MajorTopicYN="Y">Diabetic Foot</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066026" MajorTopicYN="N">Endothelial Progenitor Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diabetic foot ulcer</Keyword><Keyword MajorTopicYN="N">dipeptidyl peptidase&#x2010;4 (DPP&#x2010;4) inhibitors</Keyword><Keyword MajorTopicYN="N">randomized controlled trial (RCT)</Keyword><Keyword MajorTopicYN="N">sitagliptin</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The study protocol was approved by the Clinical Ethics Committee of West China Hospital, Sichuan University (2019174). The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40948240</ArticleId><ArticleId IdType="pmc">PMC12434403</ArticleId><ArticleId IdType="doi">10.1111/1753-0407.70156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDermott K., Fang M., Boulton A. J. M., Selvin E., and Hicks C. W., &#x201c;Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers,&#x201d; Diabetes Care 46 (2023): 209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9797649</ArticleId><ArticleId IdType="pubmed">36548709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah L., Nasiri M., and Adarvishi S., &#x201c;Literature Review on the Management of Diabetic Foot Ulcer,&#x201d; World Journal of Diabetes 6 (2015): 37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317316</ArticleId><ArticleId IdType="pubmed">25685277</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Rong G. C., and Wu Q. N., &#x201c;Diabetic Foot Ulcer: Challenges and Future,&#x201d; World Journal of Diabetes 13 (2022): 1014&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9791573</ArticleId><ArticleId IdType="pubmed">36578870</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasiri M., Fayazi S., Jahani S., Yazdanpanah L., and Haghighizadeh M. H., &#x201c;The Effect of Topical Olive Oil on the Healing of Foot Ulcer in Patients With Type 2 Diabetes: A Double&#x2010;Blind Randomized Clinical Trial Study in Iran,&#x201d; Journal of Diabetes and Metabolic Disorders 14 (2015): 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428202</ArticleId><ArticleId IdType="pubmed">25969821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanifard M., Nasiri M., Yarahmadi F., et&#xa0;al., &#x201c;Healing of Diabetic Foot Ulcer With Topical and Oral Administrations of Herbal Products: A Systematic Review and Meta&#x2010;Analysis of Randomized Controlled Trials,&#x201d; International Wound Journal 21 (2024): e14760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10867296</ArticleId><ArticleId IdType="pubmed">38356150</ArticleId></ArticleIdList></Reference><Reference><Citation>Salahi P., Nasiri M., Yazdanpanah L., Khosravi S., and Amini M. R., &#x201c;Short&#x2010;Term Effect of Dressing With Dermaheal Ointment in the Treatment of Diabetic Foot Ulcer: A Double&#x2010;Blinded Randomized Controlled Clinical Trial,&#x201d; Health Science Reports 7 (2024): e1868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10864714</ArticleId><ArticleId IdType="pubmed">38357487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper O. M., Galiano R. D., Capla J. M., et&#xa0;al., &#x201c;Human Endothelial Progenitor Cells from Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures,&#x201d; Circulation 106 (2002): 2781&#x2013;2786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12451003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini G. P., Miorin M., Facco M., et&#xa0;al., &#x201c;Circulating Endothelial Progenitor Cells are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus,&#x201d; Journal of the American College of Cardiology 45 (2005): 1449&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambataro M., Seganfreddo E., Canal F., et&#xa0;al., &#x201c;Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot,&#x201d; International Journal of Vascular Medicine 2014 (2014): 589412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929532</ArticleId><ArticleId IdType="pubmed">24624298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W., Chen D., Liu G., and Ran X., &#x201c;Autologous Stem Cell Therapy for Peripheral Arterial Disease: A Systematic Review and Meta&#x2010;Analysis of Randomized Controlled Trials,&#x201d; Stem Cell Research &amp; Therapy 10 (2019): 140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528204</ArticleId><ArticleId IdType="pubmed">31113463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuprykov O., Ando R., Reichetzeder C., et&#xa0;al., &#x201c;The Dipeptidyl Peptidase Inhibitor Linagliptin and the Angiotensin II Receptor Blocker Telmisartan Show Renal Benefit by Different Pathways in Rats with 5/6 Nephrectomy,&#x201d; Kidney International 89 (2016): 1049&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083282</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoumianakis I., Badi I., Douglas G., et&#xa0;al., &#x201c;Insulin&#x2010;Induced Vascular Redox Dysregulation in Human Atherosclerosis is Ameliorated by Dipeptidyl Peptidase 4 Inhibition,&#x201d; Science Translational Medicine 12 (2020): eaav8824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212010</ArticleId><ArticleId IdType="pubmed">32350133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahr&#xe9;n B., &#x201c;DPP&#x2010;4 Inhibition and the Path to Clinical Proof,&#x201d; Frontiers in Endocrinology 10 (2019): 376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593050</ArticleId><ArticleId IdType="pubmed">31275243</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C. Y., Shih C. M., Tsao N. W., et&#xa0;al., &#x201c;Dipeptidyl Peptidase&#x2010;4 Inhibitor Improves Neovascularization by Increasing Circulating Endothelial Progenitor Cells,&#x201d; British Journal of Pharmacology 167 (2012): 1506&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514763</ArticleId><ArticleId IdType="pubmed">22788747</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini G. P., Boscaro E., Albiero M., et&#xa0;al., &#x201c;The Oral Dipeptidyl Peptidase&#x2010;4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients with Type 2 Diabetes: Possible Role of Stromal&#x2010;Derived Factor&#x2010;1&#x3b1;,&#x201d; Diabetes Care 33 (2010): 1607&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890368</ArticleId><ArticleId IdType="pubmed">20357375</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso Y., Jojima T., Iijima T., et&#xa0;al., &#x201c;Sitagliptin, a dipeptidyl peptidase&#x2010;4 inhibitor, increases the number of circulating CD34+ CXCR4+ cells in patients with type 2 diabetes,&#x201d; Endocrine 50 (2015): 659&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">26209038</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfella R., Sasso F. C., Rizzo M. R., et&#xa0;al., &#x201c;Dipeptidyl peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes,&#x201d; Experimental Diabetes Research 2012 (2012): 892706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503302</ArticleId><ArticleId IdType="pubmed">23197976</ArticleId></ArticleIdList></Reference><Reference><Citation>Long M., Cai L., Li W., et&#xa0;al., &#x201c;DPP&#x2010;4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial&#x2013;Mesenchymal Transition and Reduction of Scarring,&#x201d; Diabetes 67 (2018): 518&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore F. J., Domingues C. C., Ahmadi N., et&#xa0;al., &#x201c;The Synergistic Effects of Saxagliptin and Metformin on CD34+ Endothelial Progenitor Cells in Early Type 2 Diabetes Patients: A Randomized Clinical Trial,&#x201d; Cardiovascular Diabetology 17 (2018): 65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934787</ArticleId><ArticleId IdType="pubmed">29724198</ArticleId></ArticleIdList></Reference><Reference><Citation>Asahara T., Murohara T., Sullivan A., et&#xa0;al., &#x201c;Isolation of Putative Progenitor Endothelial Cells for Angiogenesis,&#x201d; Science 275 (1997): 964&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">9020076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagelschmidt M., Becker D., Bonninghoff N., and Engelhardt G. H., &#x201c;Effect of Fibronectin Therapy and Fibronectin Deficiency on Wound Healing: A Study in Rats,&#x201d; Journal of Trauma 27 (1987): 1267&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">3682037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;rmann C., Linke A., Engelmann&#x2010;Pilger K., et&#xa0;al., &#x201c;The Dipeptidyl Peptidase&#x2010;4 Inhibitor Linagliptin Attenuates Inflammation and Accelerates Epithelialization in Wounds of Diabetic ob/ob mice,&#x201d; Journal of Pharmacology and Experimental Therapeutics 342 (2012): 71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22493041</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard F., Hersant B., Bosc R., and Meningaud J. P., &#x201c;The Growing Evidence for the Use of Platelet&#x2010;Rich Plasma on Diabetic Chronic Wounds: A Review and a Proposal for a New Standard Care,&#x201d; Wound Repair and Regeneration 23 (2015): 638&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">26019054</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini G. P., Bonora B. M., Cappellari R., et&#xa0;al., &#x201c;Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes,&#x201d; Journal of Clinical Endocrinology and Metabolism 101 (2016): 748&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">26695864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dei Cas A., Spigoni V., Cito M., et&#xa0;al., &#x201c;Vildagliptin, But Not Glibenclamide, Increases Circulating Endothelial Progenitor Cell Number: A 12&#x2010;Month Randomized Controlled Trial in Patients with Type 2 Diabetes,&#x201d; Cardiovascular Diabetology 16 (2017): 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324295</ArticleId><ArticleId IdType="pubmed">28231835</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger B., Klatt D., Plappert L., et&#xa0;al., &#x201c;CXCR4/MIF Axis Amplifies Tumor Growth and Epithelial&#x2013;Mesenchymal Interaction in Non&#x2010;Small Cell Lung Cancer,&#x201d; Cellular Signalling 73 (2020): 109672.</Citation><ArticleIdList><ArticleId IdType="pubmed">32428553</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojakowski W., Tendera M., Micha&#x142;owska A., et&#xa0;al., &#x201c;Mobilization of CD34/CXCR4+, CD34/CD117+, c&#x2010;met+ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients with Acute Myocardial Infarction,&#x201d; Circulation 110 (2004): 3213&#x2013;3220.</Citation><ArticleIdList><ArticleId IdType="pubmed">15533859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambeir A. M., Durinx C., Scharp&#xe9; S., and De Meester I., &#x201c;Dipeptidyl&#x2010;Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV,&#x201d; Critical Reviews in Clinical Laboratory Sciences 40 (2003): 209&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">12892317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceradini D. J., Kulkarni A. R., Callaghan M. J., et&#xa0;al., &#x201c;Progenitor Cell Trafficking is Regulated by Hypoxic Gradients Through HIF&#x2010;1 Induction of SDF&#x2010;1,&#x201d; Nature Medicine 10 (2004): 858&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">15235597</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittam A. J., Maan Z. N., Duscher D., et&#xa0;al., &#x201c;Small Molecule Inhibition of Dipeptidyl Peptidase&#x2010;4 Enhances Bone Marrow Progenitor Cell Function and Angiogenesis in Diabetic Wounds,&#x201d; Translational Research 205 (2019): 51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252504</ArticleId><ArticleId IdType="pubmed">30452888</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih C., Chen Y., Lin Y., et&#xa0;al., &#x201c;MK&#x2010;0626, a Dipeptidyl Peptidase&#x2010;4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression,&#x201d; Current Medicinal Chemistry 21 (2014): 2012&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">24059225</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiordaliso F., Maggioni S., Balconi G., et&#xa0;al., &#x201c;Effects of Dipeptidyl Peptidase&#x2010;4 (DPP&#x2010;4) Inhibition on Angiogenesis and Hypoxic Injury in Type 2 Diabetes,&#x201d; Life Sciences 154 (2016): 87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040669</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Kalka C., Masuda H., et&#xa0;al., &#x201c;Ischemia&#x2010; and Cytokine&#x2010;Induced Mobilization of Bone Marrow&#x2010;Derived Endothelial Progenitor Cells for Neovascularization,&#x201d; Nature Medicine 5 (1999): 434&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202935</ArticleId></ArticleIdList></Reference><Reference><Citation>Schatteman G. C., Hanlon H. D., Jiao C., Dodds S. G., and Christy B. A., &#x201c;Blood&#x2010;Derived Angioblasts Accelerate Blood&#x2010;Flow Restoration in Diabetic Mice,&#x201d; Journal of Clinical Investigation 106 (2000): 571&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC380249</ArticleId><ArticleId IdType="pubmed">10953032</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra G., Perrotta F., and Testa G., &#x201c;Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases,&#x201d; Current Pharmaceutical Biotechnology 19 (2018): 700&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">30332949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke X., Yang D., Liang J., et&#xa0;al., &#x201c;Human Endothelial Progenitor Cell&#x2010;Derived Exosomes Increase Proliferation and Angiogenesis in Cardiac Fibroblasts by Promoting the Mesenchymal&#x2010;Endothelial Transition and Reducing High Mobility Group Box&#xa0;1 Protein b1 Expression,&#x201d; DNA and Cell Biology 36 (2017): 1018&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">28920705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo S., Klychko E., Thorne T., et&#xa0;al., &#x201c;Exosomes from Human CD34 (+) Stem Cells Mediate Their Proangiogenic Paracrine Activity,&#x201d; Circulation Research 109 (2011): 724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201702</ArticleId><ArticleId IdType="pubmed">21835908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta N. N., Li Y., Schuyler C. A., Lopes&#x2010;Virella M. F., and Huang Y., &#x201c;DPP&#x2010;4 (CD26) Inhibitor Alogliptin Inhibits TLR4&#x2010;Mediated ERK Activation and ERK&#x2010;Dependent MMP&#x2010;1 Expression by U937 Histiocytes,&#x201d; Atherosclerosis 213 (2010): 429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">20843518</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahara Y., Tokunou T., and Ichiki T., &#x201c;Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase&#x2010;4 Inhibitor,&#x201d; Journal of Atherosclerosis and Thrombosis 25 (2018): 698&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099070</ArticleId><ArticleId IdType="pubmed">29321388</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinagra T., Merlo S., Spampinato S. F., De Pasquale R., and Sortino M. A., &#x201c;High Mobility Group Box&#xa0;1 Contributes to Wound Healing Induced by Inhibition of Dipeptidylpeptidase 4 in Cultured Keratinocytes,&#x201d; Frontiers in Pharmacology 6 (2015): 126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468832</ArticleId><ArticleId IdType="pubmed">26136686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo M. R., Barbieri M., Marfella R., and Paolisso G., &#x201c;Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients with Type 2 Diabetes: Role of Dipeptidyl Peptidase&#x2010;IV Inhibition,&#x201d; Diabetes Care 35 (2012): 2076&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3447848</ArticleId><ArticleId IdType="pubmed">22688551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Liu X., Long M., et&#xa0;al., &#x201c;NRF2 Activation by Antioxidant Antidiabetic Agents Accelerates Tumor Metastasis,&#x201d; Science Translational Medicine 8 (2016): 334ra51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27075625</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y., Bai L., Fan B., et&#xa0;al., &#x201c;Effect of SGLT2 Inhibitors Versus DPP4 Inhibitors or GLP&#x2010;1 Agonists on Diabetic Foot&#x2010;Related Extremity Amputation in Patients with T2DM: A Meta&#x2010;Analysis,&#x201d; Primary Care Diabetes 16 (2022): 156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">34930687</ArticleId></ArticleIdList></Reference><Reference><Citation>Werkman N. C. C., Driessen J. H. M., Klungel O. H., et&#xa0;al., &#x201c;Incretin&#x2010;Based Therapy and the Risk of Diabetic Foot Ulcers and Related Events,&#x201d; Diabetes, Obesity and Metabolism 26 (2024): 3764&#x2013;3780.</Citation><ArticleIdList><ArticleId IdType="pubmed">38951877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S., Ha J. H., Kim D. K., et&#xa0;al., &#x201c;Revisiting Metformin Therapy for the Mitigation of Diabetic Foot Ulcer in Patients with Diabetic Kidney Disease from Real&#x2010;World Evidence,&#x201d; International Wound Journal 21 (2023): e14370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10824619</ArticleId><ArticleId IdType="pubmed">37740678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>